68Ga-DOTA-Substance-P as a Tool for Diagnostics and Locoregional Administration Follow up of 213Bi-DOTA-Substance-P in the Course of Glioma Therapy

Gliomas, world Health Organization (WHO) grade II-IV, have been shown to consistently overexpress the transmembrane neurokinin type I receptor (NK-1). NK-1 receptors have also been detected in tumor cells in􀃀ltrating the intra- and peritumoral vasculature. Peptide Substance P is a physiological ligand for NK-1 receptor and can be labeled with various radionuclides using chelators suitable for e.g., 68Ga and 213Bi. Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8, Met (O2)11]-substance-P has been reported. In this work, 111In-DOTA-[Thi8, Met (O2)11]-substance-P was used for evaluation of receptor expression and dose distribution (Single-photon emission computed tomography (SPECT) and low-dose computed tomography (CT)). The aim of our work was to perform Positron emission tomography (PET) imaging using 68Ga-DOTA-[Thi8, Met (O2)11]-substance-P co-injected with 213Bi-DOTA-[Thi8, Met (O2)11]-substance-P therapeutic dose administered to the glioma patient via catheter directly to the cavity after tumor resection in order to assess the post-therapeutic dose distribution.

PAWLAK Dariusz;  GARNUSZEK Piotr;  MAURIN Michal;  KROLICKI Leszek;  KUNIKOWSKA Jolanta;  MORGENSTERN Alfred;  BRUCHERTSEIFER Frank;  JAKUCINSKI M;  KOZIARA H;  KROLICKI B;  MIKOLAJCZAK Renata; 

2013-05-13

Medknow

JRC80891

1450-1147 (print),    1607-3312 (online),   

www.wjnm.org,    https://publications.jrc.ec.europa.eu/repository/handle/JRC80891,